Abnormal cortical excitability in sporadic but not homozygous D90A SOD1 ALS

被引:65
作者
Turner, MR
Osei-Lah, AD
Hammers, A
Al-Chalabi, A
Shaw, CE
Andersen, PM
Brooks, DJ
Leigh, PN
Mills, KR
机构
[1] Inst Psychiat, Inst Psychiat, ANC, London SE5 8AF, England
[2] Hammersmith Hosp, Imperial Coll, Fac Med, Div Neurosci, London W12 0NN, England
[3] Hammersmith Hosp, MRC, Ctr Clin Sci, London W12 0NN, England
[4] Kings Coll Hosp London, Dept Clin Neurophysiol, Guys Kings & St Thomas Sch Med, Acad Neurosci Ctr, London SE5 9RS, England
[5] Inst Neurol, London WC1N 3BG, England
[6] Kings Coll Hosp London, Acad Neurosci Ctr, Guys Kings & St Thomas Sch Med, Dept Neurol, London SE5 9RS, England
[7] Umea Univ Hosp, Dept Neurol, S-90185 Umea, Sweden
关键词
D O I
10.1136/jnnp.2004.054429
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Excitotoxicity is one pathogenic mechanism proposed in amyotrophic lateral sclerosis (ALS), and loss of cortical inhibitory influence may be contributory. Patients with ALS who are homozygous for the D90A superoxide dismutase-1 (SOD1) gene mutation (homD90A) have a unique phenotype, associated with prolonged survival compared with patients with sporadic ALS (sALS). In this study, transcranial magnetic stimulation (TMS) was used to explore cortical excitation and inhibition. Flumazenil binds to the benzodiazepine subunit of the GABA(A) receptor, and C-11-flumazenil positron emission tomography (PET) was used as a marker of cortical neuronal loss and/or dysfunction, which might in turn reflect changes in cortical inhibitory GABAergic mechanisms. Methods: Cortical responses to single and paired stimulus TMS were compared in 28 patients with sALS and 11 homD90A patients versus 24 controls. TMS measures included resting motor threshold, central motor conduction time, silent period, intracortical inhibition (ICI), and facilitation. C-11-flumazenil PET of the brain was performed on 20 patients with sALS and nine with homD90A. Statistical parametric mapping was used to direct compare PET images from the two patient groups to identify those areas of relatively reduced cortical C-11-flumazenil binding that might explain differences in cortical excitability seen using TMS. Results: Increased cortical excitability, demonstrated by reduction in ICI, was seen in the patients with sALS but not the homD90A patients. A relative reduction in cortical C-11-flumazenil binding was found in the motor and motor association regions of the superior parietal cortices of the patients with sALS. Conclusions: A cortical inhibitory deficit in sALS was not demonstrable in a homogeneous genetic ALS population of similar disability, suggesting a distinct cortical vulnerability. C-11-flumazenil PET demonstrated that neuronal loss/dysfunction in motor and motor association areas may underlie this difference. The corollary, that there may, be relative preservation of neuronal function in these areas in the homD90A group, has implications for understanding the slower progression of disease in these patients.
引用
收藏
页码:1279 / 1285
页数:7
相关论文
共 51 条
  • [1] Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder:: evidence for a linked protective factor
    Al-Chalabi, A
    Andersen, PM
    Chioza, B
    Shaw, C
    Sham, PC
    Robberecht, W
    Matthijs, G
    Camu, V
    Marklund, SL
    Forsgren, L
    Rouleau, G
    Laing, NG
    Hurse, PV
    Siddique, T
    Leigh, PN
    Powell, JF
    [J]. HUMAN MOLECULAR GENETICS, 1998, 7 (13) : 2045 - 2050
  • [2] Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation - A clinical and genealogical study of 36 patients
    Andersen, PM
    Forsgren, L
    Binzer, M
    Nilsson, P
    AlaHurula, V
    Keranen, ML
    Bergmark, L
    Saarinen, A
    Haltia, T
    Tarvainen, I
    Kinnunen, E
    Udd, B
    Marklund, SL
    [J]. BRAIN, 1996, 119 : 1153 - 1172
  • [3] Andersen PM, 2003, AMYOTROPH LATERAL SC, V4, P62, DOI 10.1080/14660820301188
  • [4] ANDERSEN PM, 2003, MOTOR NEURON DISORDE, P207
  • [5] *AV PHARM INC, 2003, RIL RIL TABL PRESCR, P35
  • [6] El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis
    Brooks, BR
    Miller, RG
    Swash, M
    Munsat, TL
    [J]. AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS, 2000, 1 (05): : 293 - 299
  • [7] Paired-pulse transcranial magnetic stimulation: Effects of hemispheric laterality, gender, and handedness in normal controls
    Cahn, SD
    Herzog, AG
    Pascual-Leone, A
    [J]. JOURNAL OF CLINICAL NEUROPHYSIOLOGY, 2003, 20 (05) : 371 - 374
  • [8] The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function
    Cedarbaum, JM
    Stambler, N
    Malta, E
    Fuller, C
    Hilt, D
    Thurmond, B
    Nakanishi, A
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 169 (1-2) : 13 - 21
  • [9] SPECTRAL-ANALYSIS OF DYNAMIC PET STUDIES
    CUNNINGHAM, VJ
    JONES, T
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1993, 13 (01) : 15 - 23
  • [10] DAVISON C, 1941, ARCH NEUROL PSYCHIAT, V46, P1036